arrow_back Civic Audit
Share share

Boosting COVID-19 Vaccine and Treatment Production

This act aims to increase the availability of vaccines, treatments, and medical supplies essential for combating COVID-19. It allocates funding for the research, development, and procurement of these products, intending to accelerate a return to normalcy and protect public health. Citizens can expect faster access to necessary medical resources.
Key points
Allocating $20 billion for fiscal years 2021-2025 to develop and manufacture COVID-19 vaccines and treatments.
Expanding domestic production capacity to ensure sufficient supply of vaccines and therapeutics for citizens.
Supporting the manufacturing of essential medical supplies like syringes, needles, and personal protective equipment.
Requiring reports on production and distribution progress to ensure transparency and efficiency.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Print number: 117_HR_349
Sponsor: Rep. Kuster, Ann M. [D-NH-2]
Process start date: 2021-01-19
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Coronavirus Vaccine and Therapeutic Development Act of 2021

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_349.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-01-19.

What are the main provisions?

Key points include:

  • Allocating $20 billion for fiscal years 2021-2025 to develop and manufacture COVID-19 vaccines and treatments.
  • Expanding domestic production capacity to ensure sufficient supply of vaccines and therapeutics for citizens.
  • Supporting the manufacturing of essential medical supplies like syringes, needles, and personal protective equipment.
  • Requiring reports on production and distribution progress to ensure transparency and efficiency.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Kuster, Ann M. [D-NH-2].

What is the latest detailed status?

The latest detailed status is: Sponsor introductory remarks on measure. (CR H393)

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

What is the impact of this bill?

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge.

CATEGORIES

Health Public Investments